2 recruiting, 1 active not recruiting, 1 withdrawn. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 1, Recruiting 1, Withdrawn 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Refractory Indolent Non-Hodgkin Lymphoma: new trials by email Literature Review of Refractory Indolent Non-Hodgkin Lymphoma trials Research Report on Refractory Indolent Non-Hodgkin Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia Autologous Anti-CD19/CD20/CD22 CAR T-cells, Biospecimen Collection, Bone Marrow Aspiration - Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia | Phase 1 | Active not recruiting | Ohio State University Comprehensive Cancer Center | 24 | 2026-01-14 | 2026-08-26 |
| Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma Computed Tomography, Endoscopic Procedure, Involved-site Radiation Therapy (3 Fractions) - Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent Indolent B-Cell Non-Hodgkin Lymphoma | Phase 2 | Recruiting | Mayo Clinic | 112 | 2024-05-15 | 2026-04-22 |
| Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Acalabrutinib, Duvelisib - Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma | Phase 1 | Withdrawn | Narendranath Epperla | 2022-07-01 | 2022-06-07 | |
| Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies Anti-CD19/CD20/CD22 CAR T-Cells, Cyclophosphamide, Fludarabine Phosphate - Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Sumithira Vasu | 54 | 2022-06-30 | 2026-05-29 |
Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, Non-Hodgkin (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Blast Crisis (1) · Burkitt Lymphoma (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Prolymphocytic, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1)
Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoma (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Chronic Disease (2) · Disease Attributes (2) · Hematologic Diseases (2) · Leukemia (2) · Leukemia, B-Cell (2) · Leukemia, Lymphoid (2) · Lymphoma, B-Cell (2)
Biopsy (2) · Blood Component Removal (2) · Cyclophosphamide (2) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · Endoscopy (1) · Leukapheresis (1) · acalabrutinib (1) · duvelisib (1) · fludarabine (1) · fludarabine phosphate (1)
Mayo Clinic (1) · Narendranath Epperla (1) · Ohio State University Comprehensive Cancer Center (1) · Sumithira Vasu (1)
United States (3)
Sumithira Vasu, MD (2) · Brad S. Hoppe, MD, MPH (1) · Narendranath Epperla, MD (1)
R01CA276374 (1)